NVIDIA reported record profit margins in fiscal 4Q18, driven by product mix, cost benefits from a smaller nanometer node, and strong revenue growth.
As NVIDIA shifted from TSMC’s 14 nm (nanometer) node to Samsung’s 10 nm node with its Volta, it reaped the cost benefits arising from the smaller node.
Third-party retailers are leveraging the GPUs (graphics processing units) supply shortage created by crypto miners to charge very high prices for GPUs.
NVIDIA and AMD manufacture their GPUs at third-party foundries like TSMC (TSM). Mining hardware makers purchase GPUs directly from foundries.
The cryptocurrency boom saw crypto miners purchase the entire inventory of NVIDIA’s and AMD’s GPUs in calendar 2Q and 4Q17.
In fiscal 4Q18, NVIDIA’s GPU revenues rose 33% YoY and 11% sequentially to $2.46 billion, driven by strong demand for its gaming and data center GPUs.
NVIDIA has been enjoying a monopolistic position in the emerging AI market as its GPUs have been preferred by almost all cloud companies and data centers.
Fiscal 1Q is a seasonally weak quarter for NVIDIA, in general, because holiday season sales end, but this is a strong quarter for its Data Center segment.
NVIDIA (NVDA) has been witnessing rapid growth for the past seven quarters, since the launch of its Pascal GPUs (graphics processing units) in fiscal 2Q17.
NVIDIA (NVDA) has been the stock pick of many investors in 2017, as the stock has returned 10% in the past year and returned 225% in 2016.
Despite its robust efficacy profile, Aimovig has shown a safety and tolerability profile similar to that of a placebo.
Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is under review by the FDA and the European Medicines Agency.
Lutathera and SEG101 are expected to significantly strengthen Novartis’s position in the oncology segment.
Jakavi reported sales of $228.0 million in 4Q17, which is a year-over-year rise of 33.0% on a constant currency basis.
On November 8, 2017, Novartis announced the positive preliminary results from its Phase 3 trial, MONALEESA-7.
Kymriah is the first FDA-approved chimeric antigen receptor T cell (or CAR-T) therapy.
The National Cancer Institute estimates that the incidence of ALL in patients aged 20 or younger is ~3,100 in the US.
On November 6, 2017, Novartis (NVS) announced positive data from the MEASURE 1 trial, which highlighted the potential of Cosentyx in preventing the progression of disease in the majority of the…
Only 525,000 patients (or 55% of the diagnosed psoriatic arthritis patients) were eligible for treatment with biologics.
In 4Q17, Novartis’s (NVS) Cosentyx reported global sales of $615.0 million, which is a year-over-year increase of 53.0%.